生化学工業(株)
株価チャート
2026/07/10 更新株価トレンド
2026/07/10 更新株価・取引詳細
2026/07/10 更新株価
取引
決算日程
2026/07/01 更新過去の決算
| 日付 | EPS予想 | EPS実績 | サプライズ |
|---|---|---|---|
| 2016/02/01 | ¥40.50 | ¥18.93 | -53.3% |
| 2015/02/02 | ¥13.60 | ¥23.85 | +75.4% |
株主構成
2026/07/01 更新大株主
2026/07/01 更新| 機関名 | 保有比率 | 保有株数 | 変化 |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
510.5K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
350.4K | 0.00% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
181.1K | +68.31% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
|
115.8K | -10.64% | |
|
Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund
|
101.8K | -18.69% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
83.1K | -43.78% |
配当履歴
2026/07/05 更新| 年度 | 配当金 | 変化 |
|---|---|---|
| 2026 | ¥15 | -50.0% |
| 2025 | ¥30 | +7.1% |
| 2024 | ¥28 | +7.7% |
| 2023 | ¥26 | -7.1% |
| 2022 | ¥28 | - |
財務パフォーマンス
2026/07/05 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥335億 | ¥362億 | ¥394億 | ¥366億 |
| 売上総利益 | ¥180億 | ¥169億 | ¥192億 | ¥160億 |
| 営業利益 | ¥21億 | ¥4億 | ¥13億 | -¥7億 |
| 経常利益 | ¥31億 | ¥17億 | ¥19億 | ¥15億 |
| 当期純利益 | ¥22億 | ¥22億 | ¥12億 | ¥15億 |
| EPS | ¥40.49 | ¥40.08 | ¥22.25 | ¥26.99 |
| 営業利益率 | 6.32% | 1.20% | 3.39% | -1.80% |
| 貸借対照表 | ||||
| 総資産 | ¥756億 | ¥818億 | ¥839億 | ¥863億 |
| 純資産 | ¥672億 | ¥723億 | ¥732億 | ¥753億 |
| 総負債 | ¥84億 | ¥95億 | ¥107億 | ¥110億 |
| 現金 | ¥235億 | ¥154億 | ¥151億 | ¥89億 |
| 有利子負債 | ¥4億 | ¥4億 | ¥4億 | ¥4億 |
| 自己資本比率 | 88.88% | 88.37% | 87.26% | 87.21% |
| D/Eレシオ | 0.01 | 0.01 | 0.01 | 0.00 |
| キャッシュフロー | ||||
| 営業CF | ¥16億 | ¥5億 | ¥44億 | -¥13億 |
| 投資CF | ¥34億 | -¥72億 | -¥35億 | -¥35億 |
| 財務CF | -¥32億 | -¥15億 | -¥16億 | -¥17億 |
| フリーCF | -¥5億 | -¥40億 | -¥2億 | -¥74億 |
| 効率性 | ||||
| ROE | 3.33% | 3.02% | 1.66% | 1.96% |
| ROA | 2.96% | 2.67% | 1.45% | 1.71% |
最新IR情報
最新ニュース (5件)
企業情報
会社概要
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. It operates in two segments, Pharmaceuticals and LAL Business. The company offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and HERNICORE for the treatment of lumbar disc herniation. It also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, the company develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals and medical devices manufacturing processes and water quality control of dialysate used in artificial dialysis. Further, its products under development include SI-6603 for lumbar disc herniation; SI-614, a dry eye treatment; SI-613 for osteoarthritis; SI-722 to treat interstitial cystitis and bladder pain syndrome; SI-613-ETP to treat enthesopathy; and SI-449, a cross-linked chondroitin sulfate adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was incorporated in 1947 and is headquartered in Tokyo, Japan.